Most cited papers from Centre Jean Bernard

Centre Jean Bernard

What are the most cited papers from Centre Jean Bernard?

The most cited paper from Centre Jean Bernard is "FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study" (Christophe Tournigand, Thierry André, Emmanuel Achille et al., 2003), with 2,930 citations. Next come "Follicular Lymphoma International Prognostic Index" (1,544) and "Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma" (1,526).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 112 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study Christophe Tournigand, Thierry André, Emmanuel Achille et al. · Journal of Clinical Oncology	8 Dec 2003	2,930
2	Follicular Lymphoma International Prognostic Index P. Solal-Celigny · Blood Open access	11 May 2004	1,544
3	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma Thomas B. Powles et al. · New England Journal of Medicine Open access	18 Sep 2020	1,526
4	Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte Pierre Feugier, Ambro van Hoof, Catherine Sebban et al. · Journal of Clinical Oncology	2 May 2005	1,510
5	Follicular lymphoma international prognostic index P Solal-Céligny · Current Treatment Options in Oncology	Aug 2006	1,340
6	Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Hervé Avet‐Loiseau et al. · Blood Open access	5 Jan 2007	917
7	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration Wassim M. Abida et al. · Journal of Clinical Oncology Open access	14 Aug 2020	695
8	Follicular lymphoma international prognostic index. Philippe Solal-Céligny et al. · PubMed	Sep 2004	627
9	Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer Fabrice Denis, Ethan Basch, Anne-Lise Septans et al. · JAMA Open access	22 Jan 2019	588
10	EBIC-Guidelines for management of severe head injury in adults Andrew I.R. Maas, Mark Dearden, G. M. Teasdale et al. · Acta Neurochirurgica Open access	Apr 1997	582
11	Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous Leukemia François Guilhot et al. · New England Journal of Medicine Open access	24 Jul 1997	556
12	Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial Neeraj Agarwal et al. · The Lancet Open access	4 Jun 2023	533
13	Withholding and withdrawal of life support in intensive-care units in France: a prospective survey Édouard Ferrand, René Robert, Pierre Ingrand et al. · The Lancet	2001	528
14	The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline Massimo Di Maïo, Ethan Basch, Fabrice Denis et al. · Annals of Oncology Open access	21 Apr 2022	523
15	From the bench to the bedside: ways to improve rituximab efficacy Guillaume Cartron, Hervé Watier, Josée Golay et al. · Blood Open access	30 Jun 2004	523
16	Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients Fabrice Denis, Claire Lethrosne, Nicolas Pourel et al. · JNCI Journal of the National Cancer Institute Open access	15 Feb 2017	519
17	Residual Paralysis in the PACU after a Single Intubating Dose of Nondepolarizing Muscle Relaxant with an Intermediate Duration of Action Bertrand Debaene, Benoît Plaud, Marie‐Pierre Dilly et al. · Anesthesiology	May 2003	498
18	An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer George van Andel, Andrew Bottomley, Sophie D. Fosså et al. · European Journal of Cancer	7 Sep 2008	497
19	Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Jörge E. Cortes, Philippe H. Rousselot, Dong‐Wook Kim et al. · Blood	21 Dec 2006	419
20	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study Wassim M. Abida et al. · Clinical Cancer Research Open access	21 Feb 2020	398
21	Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial Jean Bourhis et al. · The Lancet Oncology	18 Jan 2012	388
22	Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study Robert Louis Ferris et al. · Annals of Oncology Open access	12 Apr 2020	379
23	Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients With Inflammatory Bowel Disease Laurent Beaugerie, Magali Svrcek, Philippe Seksik et al. · Gastroenterology Open access	27 Mar 2013	360
24	Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study Gilles Freyer, J.-F. Geay, Sandrine Touzet et al. · Annals of Oncology Open access	10 Aug 2005	344
25	Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena et al. · Journal of Thoracic Oncology Open access	15 Nov 2012	340
26	External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement Marcin Barczyński, Gregory W. Randolph, Cláudio Roberto Cernea et al. · The Laryngoscope Open access	6 Jul 2013	321
27	Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract Carole Beaumont, Patricia Leneuve, Isabelle Devaux et al. · Nature Genetics	Dec 1995	301
28	Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial Jean‐Pascal Machiels et al. · The Lancet Oncology Open access190 authors	29 Mar 2024	244
29	Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial Joël Guigay et al. · The Lancet Oncology Open access145 authors	7 Mar 2021	239
30	Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: Data from the French-Italian HHT network Gaëtan Lesca, Carla Olivieri, Nelly Burnichon et al. · Genetics in Medicine Open access	2007	228
31	Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up C. Danve-Szatanek et al. · Journal of Clinical Microbiology Open access	2004	225
32	European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma Sébastien Gaujoux et al. · British journal of surgery Open access	15 Feb 2017	224
33	Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report ETIENNE VILMER et al. · Leukemia	Dec 2000	203
34	Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial Yungan Tao et al. · Annals of Oncology Open access	28 Oct 2022	192
35	The official French guidelines to protect patients with cancer against SARS-CoV-2 infection Benoît You, Alain Ravaud, Anne Canivet et al. · The Lancet Oncology Open access	25 Mar 2020	189
36	Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19) Astrid Lièvre et al. · European Journal of Cancer Open access551 authors	8 Oct 2020	168
37	Synthetic porous ceramic compared with autograft in scoliosis surgery: A prospective, randomised study of 341 patients ANDREW O. RANSFORD, Tim Morley, Michael A Edgar et al. · Journal of Bone and Joint Surgery - British Volume Open access	1998	162
38	Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries Elisabeth Vandenberghe, Carmen Ruiz de Elvira, Fausto Rodriguez Loberiza et al. · British Journal of Haematology	Mar 2003	160
39	Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle (SFGM) Michallet et al. · British Journal of Haematology	Feb 2000	155
40	Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer Thibaut Lizee, Ethan Basch, Pierre Tremolieres et al. · Journal of Thoracic Oncology Open access	15 Feb 2019	152
41	Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukaemia Nathalie Jourdan‐Da Silva, Yves Pérel, Francoise Marie Mechinaud et al. · British Journal of Cancer Open access	2004	149
42	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid Miguel Martín, Richard H. Bell, Hugues Pierre Bourgeois et al. · Clinical Cancer Research Open access	15 Aug 2012	146
43	Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study Christopher Payan et al. · Journal of Viral Hepatitis	28 Jun 2005	143
44	First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial Karim S. Fizazi et al. · Nature Medicine Open access	4 Dec 2023	141
45	Echocardiographic assessment of pulmonary artery occlusion pressure in ventilated patients: a transoesophageal study Philippe Vignon, Ali Ait Hssain, Bruno François et al. · Critical Care Open access	19 Feb 2008	136
46	Temporal artery biopsy: A diagnostic tool for systemic necrotizing vasculitis Thierry G�n�reau, Olivier Lortholary, Pottier Ma et al. · Arthritis & Rheumatism	Dec 1999	135
47	Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study Xu-Shan Sun et al. · The Lancet Oncology	3 Aug 2020	130
48	Turner syndrome and pregnancy: clinical practice. Recommendations for the management of patients with Turner syndrome before and during pregnancy Laure Cabanes, Céline Chalas, Sophie Christin‐Maître et al. · European Journal of Obstetrics & Gynecology and Reproductive Biology	2 Jul 2010	130
49	Minor clone provides a reservoir for relapse in multiple myeloma Florence Magrangeas, Hervé Avet‐Loiseau, Wilfried Gouraud et al. · Leukemia Open access	9 Aug 2012	125
50	Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion Andréa Toma et al. · Leukemia Open access	26 Oct 2015	122

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.